Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...